Mechanisms of mTOR inhibitor resistance in cancer therapy.
about
Genetic and molecular alterations in olfactory neuroblastoma - implications for pathogenesis, prognosis and treatmentBioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trialJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesDetection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPETCompensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor TreatmentResistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signalingEffect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.FK506-binding protein 12 ligands: a patent review.Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.mTORC2 promotes cell survival through c-Myc-dependent up-regulation of E2F1.Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimusSafety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphomaNew and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Mitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformationA rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome.Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer.Everolimus induces Met inactivation by disrupting the FKBP12/Met complexA novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphomamTOR function and therapeutic targeting in breast cancer.Current development of the second generation of mTOR inhibitors as anticancer agents.PAS kinase: integrating nutrient sensing with nutrient partitioning.An overview of the mTOR pathway as a target in cancer therapy.Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling.Cancer stem cells, microRNAs, and therapeutic strategies including natural products.New insights into the management of renal cell cancer.Rapamycin-resistant effector T-cell therapy.Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis.Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.mTOR inhibitors in urinary bladder cancer.CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.
P2860
Q26743508-871138F3-C475-4D10-90E3-FE24E0BF8CC9Q27015838-2E4DBEA1-CE94-4176-9F22-15EC634F27CFQ28071388-A482642F-92AB-456C-8FD9-24B0C85CCCD6Q28487987-56A2AFC2-66B5-461C-B081-2F0B8086752DQ28550149-C5FB66A1-0B7F-400E-B2C0-B8919155506DQ30559275-B1F7755F-5515-41F5-BF23-EACD7411147FQ33416342-88B4F729-1098-4713-8D5F-268D6BFFB373Q33552565-D786EA7E-E5C4-481D-99BF-CE8BBBF23E50Q34306540-59E97E51-BF2A-421C-A664-F1C6FCE2F1ECQ34307356-A7F1A9E6-9472-4702-8CBC-10AC1A3EBBD0Q34955459-ADF9940A-F0ED-42A9-948A-DBC876F27549Q35143738-5F233D1F-3C72-4CBE-9CE4-F52F3DB27CAFQ35680679-22E76D54-794F-4587-B44F-9E43DEB8239FQ36149386-0178AF64-7878-47FA-A852-D18EE897D29AQ36173629-ED84D74B-C98D-4560-8E30-9BBAAF8552C0Q36287995-B86283A5-9ECA-4ECC-BD08-2F7BA83817E4Q36547566-D9D18654-9D6F-41AA-9793-F65C643C2EE3Q36658324-21E1D493-1B1D-4EFD-B005-DBCACE874182Q36862768-5268271F-41DB-4C4F-9E60-A6AEC6032292Q37142826-B9CADAFC-9A20-4551-BBD5-4903EE8DE288Q37228071-428F5149-FA73-46AE-80FD-A27B52F415D2Q37279290-72D91149-9278-41AC-84FB-7C47BD849890Q37306916-1E5FDB2C-CA4A-4D63-A706-06835C2489ABQ37457794-F854FF7F-5684-4565-AF45-6F700CB5AB83Q37649637-54D7739A-A4FE-4278-90D0-F70946475AA6Q37743486-7BF5BFF0-74B9-4C06-8882-E4F9221C8888Q37953476-E50C2F16-D4FC-4D22-8865-F15F45A63FEDQ37975900-0B7AB173-D9E6-4428-81AF-2F9BA589D183Q38001798-8F7B30FE-B8CB-42B7-BBAA-71E70724423AQ38016794-27B78EE9-4B43-4CC1-A9FE-4F16E942DF84Q38017247-02FDB2E8-8DF8-4D6A-946B-02CF8BD72ADEQ38023238-D8DFFEB8-4A92-4CD8-9A1F-995535A4560EQ38053049-1FA774FD-E89C-4CCE-AEA1-3901851DEB18Q38170502-B7CFAE62-5ED6-4256-BE5A-824ACFAD8C72Q38176862-74AD40AC-BDFB-4DAA-9368-B97F97286C17Q38331666-7F8DE6CC-4F5A-4E98-92C8-3250C3337A13Q38737064-94B0C554-BB00-44F6-BA0A-EB5C1610881AQ38789650-D3F6674A-C003-4302-BA33-82BA9BECF462Q38907631-96EF7619-19EA-40B0-A42A-336BA39B2493Q38978463-C7AEAB96-CF40-4127-AC79-DE8CF4E47C78
P2860
Mechanisms of mTOR inhibitor resistance in cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of mTOR inhibitor resistance in cancer therapy.
@en
Mechanisms of mTOR inhibitor resistance in cancer therapy.
@nl
type
label
Mechanisms of mTOR inhibitor resistance in cancer therapy.
@en
Mechanisms of mTOR inhibitor resistance in cancer therapy.
@nl
prefLabel
Mechanisms of mTOR inhibitor resistance in cancer therapy.
@en
Mechanisms of mTOR inhibitor resistance in cancer therapy.
@nl
P2093
P2860
P1433
P1476
Mechanisms of mTOR inhibitor resistance in cancer therapy.
@en
P2093
Jennifer S Carew
Kevin R Kelly
Steffan T Nawrocki
P2860
P2888
P356
10.1007/S11523-011-0167-8
P577
2011-03-09T00:00:00Z